Literature DB >> 12631464

Antisense in vivo knockdown of synaptotagmin I and synapsin I by HVJ-liposome mediated gene transfer modulates ischemic injury of hippocampus in opposing ways.

Miwa Iwakuma1, Takeshi Anzai, Shizuka Kobayashi, Masanori Ogata, Yasufumi Kaneda, Kousaku Ohno, Makoto Saji.   

Abstract

Neurotransmitter release during and after ischemic event is thought to be involved in excitotoxicity as a pathogenesis for the ischemic brain damage, which is mediated by excessive activation of glutamate receptors and attendant calcium overload. To ascertain the role of transmitter release from nerve terminals in promoting the ischemic neurodegeneration, we delivered antisense oligodeoxynucleotides (ODNs) to synaptotagmin I or synapsin I into the rat brain by using HVJ-liposome gene transfer technique. The antisense ODNs were injected into the lateralventricle in rats 4 days prior to transient forebrain ischemia of 20 min. With a single antisense treatment, long-lasting downregulation of the transmitter release relating protein levels at overall synaptic terminals was achieved. The antisense in vivo knockdown of synaptotagmin I prevented almost completely the ischemic damage of hippocampal CA1 neurons, while the in vivo knockdown of synapsin I markedly promoted the ischemic damage of CA1 pyramidal neurons and extended the injury to relatively resistant CA2/CA3 region. The modulation of ischemic hippocampal damage by the in vivo knockdown of synaptotagmin I or synapsin I suggests that transmitter release from terminals plays an important role in the evolution of ischemic brain damage and therefore the transmitter release strategy by the use of antisense ODNs-HVJ-liposome complex is reliable for neuroprotective therapies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12631464     DOI: 10.1016/s0168-0102(02)00233-x

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  4 in total

Review 1.  Synaptic Vesicle-Recycling Machinery Components as Potential Therapeutic Targets.

Authors:  Ying C Li; Ege T Kavalali
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

2.  CpG preconditioning regulates miRNA expression that modulates genomic reprogramming associated with neuroprotection against ischemic injury.

Authors:  Keri B Vartanian; Hugh D Mitchell; Susan L Stevens; Valerie K Conrad; Jason E McDermott; Mary P Stenzel-Poore
Journal:  J Cereb Blood Flow Metab       Date:  2014-11-12       Impact factor: 6.200

3.  Phosphoproteome Analysis Identifies a Synaptotagmin-1-Associated Complex Involved in Ischemic Neuron Injury.

Authors:  Wei Jiang; Pei Zhang; Peng Yang; Na Kang; Junqiang Liu; Yilixiati Aihemaiti; Haijun Tu
Journal:  Mol Cell Proteomics       Date:  2022-03-05       Impact factor: 7.381

4.  Neuroproteome changes after ischemia/reperfusion injury and tissue plasminogen activator administration in rats: a quantitative iTRAQ proteomics study.

Authors:  Zamir Merali; Meah MingYang Gao; Tim Bowes; Jian Chen; Kenneth Evans; Andrea Kassner
Journal:  PLoS One       Date:  2014-05-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.